Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood mental health disorder that can persist into adulthood, affects about 6% of U.S. adults. It is characterized by impulsivity, hyperactivity, and inattention, often leading to challenges such as low self-esteem, relationship difficulties, and poor academic and/or career performance. Historically, diagnosis and treatment in adults have lagged behind pediatric cases. Management typically includes stimulant and nonstimulant medications, along with behavioral therapies. Despite available treatments, an estimated one-third of adults with ADHD remain untreated. With rising awareness, clinical trials are increasingly focusing on adult patients, providing valuable data for drug labels. Understanding prescribing patterns through national claims data can help drug developers and marketers align with physician practices.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult ADHD patients?
- How have lisdexamfetamine (Vyvanse), Onyda XR, and Qelbree been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key drugs covered: Adzenys XR-ODT, Evekeo, Jornay PM, lisdexamfetamine (Vyvanse), Mydayis, Onyda XR, Qelbree, QuilliChew ER, Xelstrym
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
